Activation of the Notch1/STAT3/Twist signaling axis promotes gastric cancer progression

Carcinogenesis

Volumn 33, Issue 8, 2012, Pages 1459-1467

  Hsu, Kai Wen ^a   Hsieh, Rong Hong ^b   Huang, Kuo Hung ^a,c   Li, Anna Fen Yau ^a   Chi, Chin Wen ^a,c   Wang, Tzu Yin ^a   Tseng, Min Jen ^d   Wu, Kou Juey ^a   Yeh, Tien Shun ^a,e  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL CHUNG CHENG UNIVERSITY   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CUCURBITACIN; JAGGED1; JSI 124; NOTCH1 RECEPTOR; PROTEIN INHIBITOR; STAT3 PROTEIN; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER TISSUE; CARCINOMA CELL; CELL INVASION; CELL MIGRATION; CELL STRAIN HEK293; CELL STRAIN K 562; COLONY FORMATION; CONTROLLED STUDY; FEMALE; GENE ACTIVITY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH CANCER;

BASE SEQUENCE; CELL LINE, TUMOR; DISEASE PROGRESSION; DNA PRIMERS; HUMANS; NUCLEAR PROTEINS; PHOSPHORYLATION; RECEPTOR, NOTCH1; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STOMACH NEOPLASMS; TWIST TRANSCRIPTION FACTOR;

EID: 84865339352     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs165     Document Type: Article

References (45)

1. Smith, M.G. et al. (2006) Cellular and molecular aspects of gastric cancer. World J. Gastroenterol., 12, 2979-2990.
2. Terry, M.B. et al. (2002) The epidemiology of gastric cancer. Semin. Radiat. Oncol., 12, 111-127.
3. Polk, D.B. et al. (2010) Helicobacter pylori: gastric cancer and beyond. Nat. Rev. Cancer, 10, 403-414.
4. Zheng, L. et al. (2004) Molecular basis of gastric cancer development and progression. Gastric Cancer, 7, 61-77.
5. Wu, W.K. et al. (2010) Dysregulation of cellular signaling in gastric cancer. Cancer Lett., 295, 144-153.
6. Yin, L. et al. (2010) Notch signaling: emerging molecular targets for cancer therapy. Biochem. Pharmacol., 80, 690-701.
7. Yeh, T.S. et al. (2009) The activated Notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase-2. Cancer Res., 69, 5039-5048.
8. Sander, G.R. et al. (2004) Expression of notch receptors and ligands in the adult gut. J. Histochem. Cytochem., 52, 509-516.
9. Barnes, R.M. et al. (2009) A twist of insight - the role of Twist-family bHLH factors in development. Int. J. Dev. Biol., 53, 909-924.
10. Puisieux, A. et al. (2006) A twist for survival and cancer progression. Br. J. Cancer, 94, 13-17.
11. Zeisberg, M. et al. (2009) Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest., 119, 1429-1437.
12. Cheng, G.Z. et al. (2008) Twist is transcriptionally induced by activation of STAT3 and mediates STAT3 oncogenic function. J. Biol. Chem., 283, 14665-14673.
13. Lo, H.W. et al. (2007) Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial-mesenchymal transition in cancer cells via up-regulation of TWIST gene expression. Cancer Res., 67, 9066-9076.
14. Rosivatz, E. et al. (2002) Differential expression of the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am. J. Pathol., 161, 1881-1891.
15. Zhang, Y.Q. et al. (2007) Expression and significance of TWIST basic helix-loop-helix protein over-expression in gastric cancer. Pathology, 39, 470-475.
16. Yang, Z. et al. (2007) Up-regulation of gastric cancer cell invasion by Twist is accompanied by N-cadherin and fibronectin expression. Biochem. Biophys. Res. Commun., 358, 925-930.
17. Feng, M.Y. et al. (2009) Metastasis-induction and apoptosis-protection by TWIST in gastric cancer cells. Clin. Exp. Metastasis, 26, 1013-1023.
18. Baker, S.J. et al. (2007) Hematopoietic cytokine receptor signaling. Oncogene, 26, 6724-6737.
19. Groner, B. et al. (2008) The function of Stat3 in tumor cells and their microenvironment. Semin. Cell Dev. Biol., 19, 341-350.
20. Howlett, M. et al. (2009) Cytokine signalling via gp130 in gastric cancer. Biochim. Biophys. Acta, 1793, 1623-1633.
21. Noseda, M. et al. (2004) Notch activation results in phenotypic and functional changes consistent with endothelial-to-mesenchymal transformation. Circ. Res., 94, 910-917.
22. Timmerman, L.A. et al. (2004) Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. Genes Dev., 18, 99-115.
23. Nagao, M. et al. (2007) Cross talk between notch and growth factor/ cytokine signaling pathways in neural stem cells. Mol. Cell. Biol., 27, 3982-3994.
24. Kamakura, S. et al. (2004) Hes binding to STAT3 mediates crosstalk between Notch and JAK-STAT signalling. Nat. Cell Biol., 6, 547-554.
25. Lee, J.H. et al. (2009) Notch signal activates hypoxia pathway through HES1-dependent SRC/signal transducers and activators of transcription 3 pathway. Mol. Cancer Res., 7, 1663-1671.
26. Anant, S. et al. (1998) Twist and Notch negatively regulate adult muscle differentiation in Drosophila. Development, 125, 1361-1369.
27. Tapanes-Castillo, A. et al. (2004) Notch signaling patterns Drosophila mesodermal segments by regulating the bHLH transcription factor twist. Development, 131, 2359-2372.
28. Yeh, T.S. et al. (2003) Association of transcription factor YY1 with the high molecular weight Notch complex suppresses the transactivation activity of Notch. J. Biol. Chem., 278, 41963-41969.
29. Yang, M.H. et al. (2008) Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat. Cell Biol., 10, 295-305.
30. Hsieh, J.J. et al. (1996) Truncated mammalian Notch1 activates CBF1/ RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2. Mol. Cell. Biol., 16, 952-959.
31. Hsu, K.W. et al. (2008) The activated Notch1 receptor cooperates with alpha-enolase and MBP-1 in modulating c-myc activity. Mol. Cell. Biol., 28, 4829-4842.
32. Liao, W.R. et al. (2007) The CBF1-independent Notch1 signal pathway activates human c-myc expression partially via transcription factor YY1. Carcinogenesis, 28, 1867-1876.
33. Hsu, K.W. et al. (2009) MBP-1 suppresses growth and metastasis of gastric cancer cells through COX-2. Mol. Biol. Cell, 20, 5127-5137.
34. Chen, J.H. et al. (2006) Effects of COX-2 inhibitor on growth of human gastric cancer cells and its relation to hepatocyte growth factor. Cancer Lett., 239, 263-270.
35. Zhou, S. et al. (2001) Nuclear localization of CBF1 is regulated by interactions with the SMRT corepressor complex. Mol. Cell. Biol., 21, 6222-6232.
36. Wen, Z. et al. (1995) Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell, 82, 241-250.
37. Androutsellis-Theotokis, A. et al. (2006) Notch signalling regulates stem cell numbers in vitroand in vivo. Nature, 442, 823-826.
38. Nelson, K.L. et al. (1998) Activation of STAT3 by the c-Fes protein-tyrosine kinase. J. Biol. Chem., 273, 7072-7077.
39. Monsalve, E. et al. (2009) Notch1 upregulates LPS-induced macrophage activation by increasing NF-kappaB activity. Eur. J. Immunol., 39, 2556-2570.
40. Palmieri, M. et al. (1999) Interaction of the nuclear protein CBF1 with the kappaB site of the IL-6 gene promoter. Nucleic Acids Res., 27, 2785-2791.
41. Wang, T. et al. (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med., 10, 48-54.
42. Kortylewski, M. et al. (2005) Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med., 11, 1314-1321.
43. Kujawski, M. et al. (2008) Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest., 118, 3367-3377.
44. Ma, J. et al. (2010) Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J. Clin. Invest., 120, 103-114.
45. Yue, P. et al. (2009) Targeting STAT3 in cancer: how successful are we? Expert Opin. Investig. Drugs, 18, 45-56.